The role of antibiotic prophylaxis in totally implantable venous access device placement: results of a single-center prospective randomized trial

2011 ◽  
Vol 202 (1) ◽  
pp. 10-15 ◽  
Author(s):  
Hasan Karanlik ◽  
Sidika Kurul ◽  
Pinar Saip ◽  
Ersin Selcuk Unal ◽  
Fatma Sen ◽  
...  
2010 ◽  
Vol 1 (6) ◽  
pp. 1029-1031 ◽  
Author(s):  
SHINICHIRO KOKETSU ◽  
SHINISHI SAMESIMA ◽  
SATOMI YONEYAMA ◽  
TOSHIYUKI OKADA ◽  
SHIGERU TOMOZAWA ◽  
...  

2012 ◽  
Vol 23 (3) ◽  
pp. 358-362 ◽  
Author(s):  
Anne M. Covey ◽  
Franz W. Toro-Pape ◽  
Raymond H. Thornton ◽  
Crystal Son ◽  
Joseph Erinjeri ◽  
...  

2004 ◽  
Vol 9 (4) ◽  
pp. 221-225
Author(s):  
Kelli Rosenthal

Abstract Immunologic Heparin-induced Thrombocytopenia (HIT Type II) results from heparin exposure in any form, and can result in major intravascular thrombotic events, ischemia, and death. Type II HIT occurs in approximately 1 to 3% of patients receiving heparin and can occur at any dose or via any route of administration, making it a potentially serious complication of routine central venous access device (CVAD) maintenance with heparin flush locking techniques. A review of the clinical literature reveals largely anecdotal information implicating the role of heparin flush solutions in its development. Further study is needed to more specifically identify the likelihood of developing HIT from vascular access device related causes.


2014 ◽  
Vol 22 (6) ◽  
pp. 1943-1949 ◽  
Author(s):  
Chun-Yu Wu ◽  
Feng-Sheng Lin ◽  
Yi-Chia Wang ◽  
Wei-Han Chou ◽  
Wen-Ying Lin ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document